Recent Studies from Nanjing Medical University Add New Data to Assisted Reproductive Technology (Feasibility analysis of incorporating infertility into medical insurance in China): Technology – Assisted Reproductive Technology

2022 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Researchers detail new data in assisted reproductive technology. According to news reporting out of Nanjing, People’s Republic of China, by NewsRx editors, research stated, “In recent years, the incidence of infertility has been increasing gradually, while the natural rate of population growth is declining or even at zero growth. China is observed to enter a depth of aging society, leading to more severe infertility.”

The news reporters obtained a quote from the research from Nanjing Medical University: “Infertility patients face many predicaments, and many unreasonable behaviors existed in seeking medical diagnosis and treatment, of which the main influencing factor is economic condition. In China, Beijing has taken the lead in providing medical insurance for 16 assisted reproductive technology items. Assuming that all infertile couples with the option of assisted reproduction are treated, there would be a huge market gap. The reimbursement rate can be adjusted based on some factors within the affordable range of the medical insurance fund. Progress on infertility coverage in other countries was also reviewed. This paper cited the data of medical insurance funds in China in the recent 4 years as a reference. Based on the data, it is not currently able to cover all the costs of infertility diagnosis and treatment during the research period, but it is feasible to access selective reimbursement and subsidies for those in particular need as well as to develop some commercial insurances. There is a big gap in the application of assisted reproductive technology between China and developed countries.”

According to the news editors, the research concluded: “More comprehensive and constructive policies should be formulated countrywide to standardize the market. Assisted reproduction-related technologies and acceleration of the domestic medical apparatus and instrument replacement should be improved to reduce the cost.”

For more information on this research see: Feasibility analysis of incorporating infertility into medical insurance in China. Frontiers in Endocrinology, 2022,13. (Frontiers in Endocrinology - http://www.frontiersin.org/endocrinology). The publisher for Frontiers in Endocrinology is Frontiers Media S.A.

A free version of this journal article is available at https://doi.org/10.3389/fendo.2022.967739.

Our news journalists report that more information may be obtained by contacting Lin Wang, State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, People’s Republic of China. Additional authors for this research include Ye Zhu, Tong Wang, Xinrong Xu, Qiuqin Tang, Jinhui Li, Yanchen Wang, Weiyue Hu, Wei Wu. Our reports deliver fact-based news of research and discoveries from around the world.